Will biotechnology firms in 2016 keep up the momentum that resulted in a record-breaking $7.4bn in US venture capital raised by the industry last year? It's possible if early-stage funding keeps up January's brisk pace, but it's too soon to tell if February will be a boom or a bust.
Yumanity disclosed a $45m Series A venture funding round on Feb. 10 to pay for drug discovery focused on protein...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
